Continuous Glucose Monitoring System Feasibility in Youth With T2D

Eligibility Criteria

• 1. Age 8- 20 years at the time of consent.
• 2. Clinical diagnosis of type 2 diabetes.
• 3. Duration of type 2 diabetes at least 4 weeks.
• 4. HbA1C ≥ 6.5% .
• 5. Stable medication regimen (No medication changes and no change in basal insulin dose by more than 20% in the 2 weeks prior to enrollment).
• 6. Naïve to CGM use.
• 7. English or Spanish speakers.
• 8. Willing to abide by recommendations and study procedures.
• 9. Willing and able to sign the Informed Consent Form (ICF) and/or has a parent or guardian willing and able to sign the ICF.
• 10. Participant and parent(s)/guardian(s) willingness to participate in all training sessions as directed by study staff. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
• 1. Pancreatic autoantibody positivity (GAD-65, insulin, IA-2, ICA 512, Zn-T8).
• 2. Plan for undergoing bariatric surgery during the study period.
• 3. Known history of significant mental illness or developmental delay impacting the ability to complete study activities independently.
• 4. Known history of adrenal insufficiency, or ongoing renal or hepatic disease.
• 5. Pregnancy or lactation.
• 6. Currently undergoing cancer treatment or systemic treatment with steroids.
• 7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.